USCC Home
 
U.S. Chamber of Commerce Join Today
U.S. Chamber of Commerce
USCC Home Small Business Center Issues and Advocacy Media Center Chambers Associations Members

nav
Business & Society
Capital Markets
Institute for a Competitive Workforce
Institute Program
Let's Rebuild America Initiative
Litigation Center
About NCLC
Case List
Join
News & Events
National Chamber Foundation
Regulatory Cooperation
Research and Analysis
Workforce Freedom Initiative
Join
navbottom

Related
About the U.S. Chamber of Commerce
Careers
Events Calendar
FAQs
Publications
related_Bottom

Related
 
 
 
 
 
related_Bottom

 
Programs > Litigation Center

June 3, 2008 Contact: Sheldon Gilbert 202-463-5685

Chamber Asks High Court to Defer to FDA Drug Labeling
Federal Law Should Trump State Tort Lawsuits 

WASHINGTON, D.C.—The U.S. Chamber's National Chamber Litigation Center (NCLC) today urged the Supreme Court to reject a Vermont Supreme Court decision upholding a jury's verdict that a prescription drug manufacturer failed to adequately warn of the risks associated with an anti-nausea drug, even though the Food and Drug Administration designed the drug label. The case, Wyeth v. Levine, will be heard by the High Court this fall.

"Congress has given the FDA the authority to regulate what are the most appropriate drug labels, and states and juries shouldn't be allowed to second-guess the judgment of those expert regulators," explained Robin Conrad, executive vice president of NCLC. "This case is about leaving regulation in the hands of experts, not placing it in the hands of trial lawyers."

In its amicus brief, NCLC urged the Court to reject independent state tort liability for drug labeling. According to the brief, FDA approval of a drug reflects the agency's expert judgment that the benefits of the drug outweigh the risks. FDA-designed drug labels reflect the agency's determination that a drug is safe and effective under certain conditions of use. State laws or jury decisions that exaggerate a particular risk could harm the public by discouraging the appropriate use of an otherwise beneficial drug, according to NCLC. Moreover, if multiple regulators including federal agencies, states and juries are allowed to set different and competing labeling standards, consumers could be so overwhelmed by excessive warnings that the more meaningful risk information provided by the FDA would lose its significance.

"Drug manufacturers are subjected to multiple, competing layers of regulation, including the federal government, state governments and juries," said Conrad. "Regulation by jury is costly and unpredictable, and often forces businesses to either pull beneficial drugs off the market or pass the costs of regulation on to consumers."

NCLC is the public policy law firm of the U.S. Chamber of Commerce. The U.S. Chamber is the world's largest business federation representing more than 3 million businesses and organizations of every size, sector and region.


 
 
Join | Login | Search | Sitemap | Contact Us | Terms & Conditions | Privacy Policy
 
Copyright © 2008 U.S. Chamber of Commerce 1615 H St NW Washington DC 20062-2000 All Rights Reserved
Advancing human progress through an economic, political and social system based on individual freedom, incentive, initiative, opportunity, and responsibility.